Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug97 | ARCT-021 Dose 1 Wiki | 0.71 |
drug99 | ARCT-021 Dose 3 Wiki | 0.71 |
drug98 | ARCT-021 Dose 2 Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D000257 | Adenoviridae Infections NIH | 0.32 |
D018352 | Coronavirus Infections NIH | 0.11 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
The primary objective of this study is to describe the safety and tolerability of one IM dose of AZD1222 followed by one IM dose of rAd26-S in adults ≥ 18 years of age
Description: Incidence of Serious Adverse Events (SAEs) post first dose until the study end
Measure: Incidence of Serious Adverse Events (SAEs) post first dose until the study end Time: from Day 1 until Day 180Description: Incidence of unsolicited AEs for 28 days post each dose
Measure: Incidence of unsolicited Adverse Events (AEs) for 28 days post each dose Time: from Day 1 to Day 28 and from Day 29 to Day 57Description: Incidence of local and systemic solicited AEs for 7 days post each dose
Measure: Incidence of local and systemic solicited AEs for 7 days post each dose Time: from Day 1 to Day 8 and From Day 29 to Day 36Description: Incidence of AESIs post first dose until study end (Day 180)
Measure: Incidence of Adverse events of special interest (AESIs) post first dose until study end Time: from Day 1 to Day 180Description: assessment of time course of antibody to Spike protein of one IM dose of AZD1222 followed by one IM dose of rAd26-S
Measure: assessment of time course of antibody to Spike protein of one IM dose of AZD1222 followed by one IM dose of rAd26-S Time: On Day 1 and on Day 29Description: Determination of anti-SARS-CoV-2 neutralising antibody levels in serum following one IM dose of AZD1222 followed by one IM dose of rAd26-S
Measure: Determination of anti-SARS-CoV-2 neutralising antibody levels in serum following one IM dose of AZD1222 followed by one IM dose of rAd26-S Time: On Day 1 and on day 29Description: Proportion of participants who have a post treatment seroresponse (≥ 4-fold rise in titers from day of dosing baseline value to 28 days post each dose) as measured by SARS-CoV-2 antibodies to Spike protein
Measure: Proportion of participants who have a post treatment seroresponse Time: from Day 1 (before dose) to Day 28 and from Day 29 (before dose) to Day 57The purpose of this study is to identify early signals of efficacy or harm associated with convalescent plasma therapy in a population of Veteran inpatients with coronavirus disease 2019 (COVID-19).
Description: Death at any time after admission recorded in the electronic health record. Specific estimates of risk of death will be produced for 7 days, 14 days, 21 days and 28 days, and total deaths.
Measure: All-cause mortality Time: up to 28 daysDescription: Number of days from index date to first intubation in non-mechanically ventilated patients
Measure: Time to first intubation Time: 28 daysDescription: Number of days from index date to hospital discharge
Measure: Time to hospital discharge Time: 28 daysDescription: Number of days from index date to death from any cause
Measure: Time to all-cause mortality Time: 28 daysDescription: Long-term outcomes will include death at one year following the index date.
Measure: All-cause mortality Time: 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports